Trial Profile

An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lisavanbulin (Primary)
Indications Cholangiocarcinoma; Glioblastoma; Glioma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Basilea Pharmaceutica

Most Recent Events

06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
08 Mar 2023 Status has been changed to discontinued.
08 Mar 2023 Results from phase 2, presented at the 21st International Congress on Targeted Anticancer Therapies

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com